PMID-24818783 – Growth Hormone Therapy: Cancer and Cardiovascular Risk Meta-Analysis
Deodati A et al. "Growth hormone therapy and risk of mortality and cancer in patients with growth hormone deficiency: a meta-analysis," Growth Hormone & IGF Research, 2014;24(4):105-111.
Quick Reference
| Property | Value |
|---|---|
| PMID | 24818783 |
| DOI | — |
| Year | 2014 |
| Journal | Growth Hormone & IGF Research |
| Study Type | Systematic Review / Meta-analysis |
| Evidence Level | I |
| Sample | Pooled data from multiple cohort studies of GH-treated patients |
| Peptide(s) Studied | GH-axis peptides (exogenous GH therapy as proxy) |
Key Findings
- Cancer standardized incidence ratio (SIR) of 2.74 in GH-treated patients compared to general population
- Elevated risk appeared most prominent in certain cancer types rather than across all cancers
- Cardiovascular risk was also elevated in the GH-treated cohort
- Critical confounders noted: GH-treated populations have underlying conditions (e.g., pituitary tumors, craniopharyngioma, prior radiation therapy) that independently elevate cancer risk
- The authors themselves acknowledge that the elevated SIR likely reflects confounding by indication rather than a direct GH effect
- When restricted to patients without prior malignancy or radiation history, the risk signal attenuated substantially
Study Design
Systematic review and meta-analysis of observational cohort studies evaluating long-term cancer incidence and cardiovascular outcomes in patients receiving growth hormone replacement therapy. Included pediatric and adult GH-deficient populations.
Limitations
- Confounding by indication is a major limitation — GH-deficient patients often have underlying conditions (craniopharyngioma, pituitary tumors, prior cranial radiation) with elevated baseline cancer risk
- No ability to distinguish direct GH/IGF-1 effects from underlying disease effects
- Heterogeneous GH dosing regimens and follow-up durations
- Publication-era studies may reflect older monitoring practices
Clinical Relevance
This meta-analysis initially appears alarming (SIR 2.74), but the confounders are critical context. It must be interpreted alongside the much larger Johannsson 2022 study (PMID-35368070, n=15,809) and the Boguszewski 2022 consensus (PMID-35319491), both of which found no increased cancer risk with properly monitored GH replacement. For GH-axis peptide protocols, this study underscores the importance of cancer screening and monitoring IGF-1 levels, but should not be cited in isolation as evidence that GH-stimulating peptides cause cancer.
Related
#research #systematic-review #evidence-level-I #cancer